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Received December 17, 2015; accepted May 1, 2016AbstractBackground: The purpose of this study was to evaluate the prostate cancer yield rate of targeted transrectal ultrasound (TRUS)-guided biopsy
with cognitive magnetic resonance imaging (MRI) registration without concurrent systematic biopsy in patients with previous negative sys-
tematic TRUS-guided biopsy results and persistently elevated prostate-specific antigen (PSA) levels.
Methods: In this prospective study conducted from August 2013 to January 2015, patients with at least one previous negative systematic TRUS-
guided biopsy and persistently high PSA (4 ng/mL) levels were referred for multiparametric MRI (mpMRI). Those patients with suspicious
findings on mpMRI received a subsequent cognitive MRI-TRUS fusion biopsy. The cancer-detection rate, tumor location, and Gleason score
were confirmed, and PSA-related data were compared between cancer-yield and noncancer-yield groups.
Results: In total, 48 patients were included in this study. MRI was designated to be four and five in 17 patients. Fifteen patients received a
cognitive fusion-targeted biopsy, and prostate cancers were detected in 10 patients. The cancer-detection rate was 20.8% (10/48), and the positive-
predictive value of MRI was 66.7%. No significant differences were observed in the PSA level, PSAvelocity, or transitional zone volume between
the cancer-yield and noncancer-yield groups; however, the corresponding difference in PSA transitional zone density was significant ( p¼ 0.025).
Conclusion: Cognitive MRI-TRUS fusion-targeted biopsy without concurrent systematic biopsy can detect significant prostate cancer in patients
with previous negative systematic biopsy results and persistently elevated PSA levels. Noncancer-yield patients should undergo active sur-
veillance and further follow-ups.
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In Taiwan, the incidence rate of prostate disease has
elevated along with increases in the aging population.1 The
prostate-specific antigen (PSA) test is a fast and convenient
method for prostate-cancer screening and is widely used. The
PSA test has a high level of sensitivity, but low specificity for
prostate cancer. Many benign prostate diseases, includingsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND
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elevated PSA level.2 For patients with elevated PSA levels,
transrectal ultrasound (TRUS)-guided biopsy is the standard
procedure for diagnosing prostate cancer; however, this is an
invasive procedure with considerable complications, including
infection, bleeding, and voiding difficulty.3 Furthermore, a
high false-negative rate (39e52%) was reported for systematic
prostate biopsy.4 Because the PSA test is used more
frequently, the number of patients with an increased PSA
level, but a negative prostate biopsy, is high, leading to diffi-
culties in clinical management and causing patient anxiety and
possible treatment delays. Considering the unreliability of the
PSA test and systematic TRUS-guided prostate biopsy in
diagnosing prostate cancer, advanced diagnostic methods for
visualizing and subsequently guiding biopsies are imperative
to improved patient care.
Magnetic resonance imaging (MRI) is a direct and
noninvasive method for pretreatment assessments of prostate
cancer. Combining anatomical imaging (high resolution
T2-weighted images) with functional imaging techniques,
including diffusion-weighted imaging (DWI), dynamic
contrast-enhanced (DCE) imaging, and MR spectroscopy [i.e.,
multiparametric MRI (mpMRI)], has significantly improved
the diagnostic accuracy for prostate cancer by enabling tumor
detection and localization.5e9 Many studies reported that MRI
scans increased cancer-detection rates in patients with elevated
PSA levels and negative systematic TRUS-guided biopsy
reports4,10e15; however, the technical parameters of mpMRI,
criteria for selecting the lesions for targeted biopsy, and the
targeting approach differ among these studies. Here, we
evaluated the prostate cancer-yield rate of cognitive MRI-
TRUS fusion-targeted biopsy for mpMRI-visible lesions in
patients with elevated PSA levels and previous negative sys-
tematic TRUS-guided biopsy.
2. Methods2.1. Patient recruitmentThis institutional review board-approved prospective study
recruited consecutive patients with elevated PSA levels
(4 ng/mL) and at least one previous negative systematic
TRUS-guided biopsy and referred them for an MRI scan at the
urology clinic of our institution from August 2013 to January
2015. Patients with pacemaker implantation or other contra-
indications for MRI examinations were excluded, and
informed consent was obtained from all patients.2.2. Imaging protocolAll imaging studies were performed using a 3.0 T MRI
scanner (MR750, GE Medical Systems, Milwaukee, WI, USA)
and a body coil for transmission and a four-coil phased-array
torso coil for reception. The MRI protocol conformed to the
European Society of Urogenital Radiology (ESUR) guide-
lines.16 Axial T1-weighted spin-echo MR images (repetition
time/echo time ¼ 400/9 ms; matrix size ¼ 320  224; field ofview ¼ 16  16 cm; excitation numbers ¼ 2; and slice
thickness/gap ¼ 3 mm/0 mm) were obtained for detecting
intraglandular hemorrhage. Subsequent T2-weighted fast spin-
echo MR images (repetition time/echo time ¼ 3000e4000/
90 ms; echo train length ¼ 17; matrix size ¼ 512  256; field
of view ¼ 16  16 cm; excitation numbers ¼ 4; and slice
thickness/gap ¼ 3 mm/0 mm) were obtained in the axial,
sagittal, and coronal planes of the prostate and seminal vesicles
for identifying the prostate zonal anatomy, three-dimensional
(3D) diameter of the transitional zone, and pathology. Axial
diffusion-weighted single-shot echo-planar imaging using a
sensitivity encoding technique (SENSE-DWI; repetition time/
echo time¼ 8500/minimum ms; matrix size¼ 128 128; field
of view ¼ 16 16 cm; excitation numbers¼ 4; slice thickness/
gap ¼ 3 mm/0 mm; axial scan b-factor values ¼ 0 and 1000 s/
mm2 for three directions of the gradient; sensitivity encoding
(SENSE) reduction factor ¼ 2) were subsequently performed,
and the corresponding apparent diffusion-coefficient maps were
generated. For the 3D DCE study, images were obtained with
an interval between each phase of <10 s, and subtraction was
routinely performed to facilitate interpretation.2.3. MRI reportingTwo radiologists, one with >10-years (S.H.S) and the other
with 2-years (H.T.L) experience in urogenital radiology,
reviewed the images together and consensually identified
suspicious lesions. The locations of the lesions were assigned
according to the 27 regions-of-interests described in the
Prostate Imaging Reporting and Data System (PI-RADS).16
The diameters of the transitional zone on the axial, sagittal,
and coronal planes were recorded, and the transitional zone
volume was approximated as the product of all three axial
diameters and p divided by six. The transitional zone density
for PSA (PSATZ) was calculated by dividing the PSA level by
the transitional zone volume.2.4. Cognitive MRI-TRUS fusion biopsyPatients with suspicious lesions following mpMRI received
a subsequent target biopsy. TRUS-guided biopsy was per-
formed using an Acuson S3000 ultrasound system (Siemens
Medical Solutions, Malvern, PA, USA) with an EC9-4 endo-
cavitary transducer. The patient was placed in the left lateral
decubitus position with bent knee. After sterilization, cogni-
tive MR-targeted biopsy was performed under TRUS-guidance
in axial scan. Cognitive registration of the suspicious area was
localized through both gray scale and color Doppler images.
The lesion was identified on the basis of the zonal anatomy
described or imaging landmarks, including bladder neck, cyst,
or hyperplastic nodules. A needle adapter was attached to the
ultrasound transducer for placing the biopsy needle. An 18-
gauge/20-cm spring-loaded biopsy needle (Temno Evolution;
BD Biosciences, Franklin Lakes, NJ, USA) was used for bi-
opsy. Lesion targeting and tissue acquisition were performed
under continuous real-time ultrasound monitoring. Three
needle passes were performed for each target lesion.
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cussed with the patient. If there was agreement, systemic bi-
opsy of 12 cores was subsequently performed on the patient
after targeted biopsy. After biopsy, TRUS was performed to
survey the entire prostate gland for identifying hematoma.2.5. Statistical analysesClinical data on serial PSA levels, previous biopsy date(s),
and pathology reports (including Gleason score) were recor-
ded for each patient. The updated PI-RADS version 2 score
was assigned for each lesion for analysis according to the
consensus of the two radiologists.17 Epstein criteria were used
to define clinically significant cancer: any Gleason pattern 4 or
Gleason 3 þ 3 disease with core length 50% and/or > two
cores positive on the standard 12-core TRUS-guided biopsies.
Clinically significant prostate cancer on fusion biopsy was
defined as any Gleason pattern 7e10 and/or Gleason 6 disease
and an MRI-visible lesion >0.5 cm3.17,18 The cancer-detection
rate and positive-predictive value of the MRI scans were
calculated. The transitional zone volume and PSA-related data
considering PSA level, PSA velocity, and PSATZ were
recorded. We used an independent sample t test (SPSS version
21.0 software; IBM, Armonk, NY, USA) to compare the PSA
level, PSA velocity, transitional zone volume, and PSATZ
between the cancer-yield and noncancer-yield groups. If the
independent sample t tests differed significantly, we used the
receiver operating characteristic curve (ROC) and Youden
index to determine the cut-off value.
3. Results
Forty-eight patients were included in this study, with a
mean age of 65.7 years (48e78 years).3.1. MRI studyThe MRI scan analysis resulted in a PI-RADS score 2 in
25 patients, PI-RADS score ¼ 3 in six patients, PI-RADS
score ¼ 4 in five patients, and PI-RADS score ¼ 5 in 12
Table 1
Clinical profiles of patients in the cancer-yield group.
No. Age
(y)
Location PI-RADS
(v2)
Biopsy result Operation result
Gleason score Gleason score Stage
1 62 TZa 5 3þ 3 3þ 4 pT3a
2 74 TZa 5 3þ 3 3þ 4 pT2c
3 67 TZa 5 4þ 3 4þ 3 pT2c
4 66 TZa 5 3þ 4 3þ 4 pT3a
5 72 TZa 5 4þ 3 NA NA
6 57 PZa 4 3þ 4 3þ 4 pT3a
7 59 PZpl 5 3þ 4 3þ 4 pT3a
8 71 TZa 5 3þ 3 3þ 3 pT2c
9 58 TZa 5 4þ 4 4þ 3 pT3a
10 79 PZpl 5 4þ 3 NA NA
NA¼ not available (patients did not receive surgery); PI-RADS ¼ Prostate
Imaging Reporting and Data System; PZa ¼ anterior peripheral zone;
PZpl ¼ posterior lateral peripheral zone; pT ¼ posterior transitional zone;
TZa ¼ anterior transitional zone.patients. Two PI-RADS score ¼ 4 patients declined to receive
a biopsy and opted for follow-up. The remaining 15 patients
with PI-RADS 4 received a cognitive MRI-TRUS fusion
biopsy, with cancer successfully detected in 10 patients (Table
1). The lesions were iso- or low echogenicity, and may have
shown hypervascularity according to color Doppler study. The
mean time between the previous biopsy and MRI for cognitive
registration was 771 days (53e3141 days), and the mean time
between MRI and systematic TRUS-guided biopsy was 25.1
days (1e84 days). The cancer-detection rate was 20.8% (10/
48). Nine cancer-positive patients exhibited PI-RADS scores
of 5, and one patient had a PI-RADS score of 4. The cancer-
yield rates for patients with PI-RADS scores of 5 and 4 were
75% (9/12) and 33.3% (1/3), respectively. The positive-
predictive value of the targeted biopsy was 66.7% (10/15),
and the average size of the 10 detected lesions was 2.17 cm
(1.0e3.9 cm). Eight of the 10 patients had lesions in the
anterior part of the prostate gland (Figs. 1 and 2), and two
patients had lesions in the posterior lateral peripheral zone.3.2. PathologyOf the 10 cancer patients, three, three, three, and one pa-
tient showed Gleason scores of 3þ 3, 3þ 4, 4þ 3, and 4þ 4,
respectively (Table 1). All of the prostate cancers detected in
this study were clinically significant. Five patients received
both targeted and systematic TRUS-guided biopsy during the
same section, and all of the cores from systematic biopsy
showed negative results. Eight of the 10 cancer patients
received a prostatectomy. The Gleason score of the final pa-
thology was concordant with the biopsy results in five patients,
upgraded in two patients, and downgraded in one patient.3.3. PSA-related dataAge, transitional zone volume, and PSA-related data
associated with the cancer-yield and noncancer-yield groups
are compared in Table 2. Although the mean PSA level was
higher in the cancer-yield group (mean 21.57 ng/mL;
4.89e56.33 ng/mL) as compared with the noncancer yield
group (mean 11.72 ng/mL; 4.82e27.23 ng/mL), the effect size
was large, resulting in differences that were not significant
( p¼ 0.123). The difference in the PSA velocity between the
two groups was also not significant ( p¼ 0.431). Also, the
transitional zone volume was larger in the noncancer-yield
group ( p¼ 0.057). PSATZ was significantly higher in the
cancer-yield group (1.16 ng/mL/cm3; 0.25e3.15) relative to
that observed in the noncancer-yield group (0.40 ng/mL/cm3;
0.11e1.63) ( p¼ 0.024). A cut-off value of 0.45 ng/mL/cm3
was calculated. The area under the ROC curve was 0.841, and
the sensitivity and specificity using this cut-off value were
90% and 67.6%, respectively.3.4. Follow-up statusImmediately after the TRUS-guided biopsy procedure, only
one patient experienced anal pain and bleeding during
Fig. 1. A 62-year-old man with elevated PSA (14.33 mg/dL) and previous negative-systematic biopsy. (A) MRI (from left to right: T2-weighted coronal scan, T2-
weighted axial scan, DWI, corresponding ADC map, and postcontrast-enhanced T1-weighted subtraction imaging) revealed a tumor nodule at right apex (arrows);
and (B) transrectal ultrasound (from left to right: targeting diagram, sagittal scan, and axial scan) localized the nodule at corresponding area (open arrows). The
targeted biopsy yielded prostate adenocarcinoma (Gleason score 3þ 3). The final histopathological result of radical prostatectomy was Gleason score 3þ 4, stage
pT3a. ADC¼ apparent diffusion coefficient; DWI¼ diffusion-weighted imaging; MRI¼magnetic resonance imaging; PSA¼ prostate-specific antigen.
Fig. 2. A 57-year-old man with elevated PSA (4.89 mg/dL) and previous negative-systematic biopsy. (A) MRI (from left to right: T2-weighted sagittal scan, T2-
weighted axial scan, DWI, corresponding ADC map, and postcontrast-enhanced T1-weighted subtraction imaging) demonstrated a suspicious lesion at the anterior
horn of the right peripheral zone (arrows); and (B) transrectal ultrasound (from left to right: targeting diagram, sagittal scan, and axial scan) identified the lesion at
the corresponding area (open arrows). Targeted biopsy was performed (curved open arrow: biopsy needle) and revealed prostate adenocarcinoma (Gleason score
3þ 4). The final histopathological result of radical prostatectomy was Gleason score 3þ 4, stage pT3a. ADC¼ apparent diffusion coefficient; DWI¼ diffusion-
weighted imaging; MRI¼magnetic resonance imaging; PSA¼ prostate-specific antigen.
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retention. One patient (6.7%) experienced systemic infection
and required intravenous antibiotics treatment.
The average follow-up duration for the 38 noncancer-yield
patients was 461.5 days (244e810 days), with none of them
found to have cancer during the follow-up period.4. Discussion
The low specificity of the PSA test and the low sensitivity
of TRUS-guided systematic biopsy have resulted in a high
number of patients diagnosed with elevated PSA levels and
negative TRUS-guided systematic biopsy results. The
Table 2
Comparison of PSA-related data between the cancer-yield and noncancer-
yield groups.
Cancer-yield
group
Noncancer-yield
group
p
Age (y) 66.5± 7.472 63.34± 6.166 0.174
PSA (ng/mL) 21.57± 18.07 11.72± 6.52 0.123
PSA velocity (ng/mL/mo.) 0.673± 0.57 0.398± 0.80 0.431
Transitional zone volume (cm3) 22.29± 13.23 38.69± 25.55 0.057
PSA transitional zone
density (ng/mL/cm3)
1.16± 0.87 0.40± 0.32 0.024
PSA¼ prostate-specific antigen.
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when only follow-ups are arranged, this can result in
tremendous anxiety among patients and increased risk of
delayed diagnoses. Various techniques allowing tumor visu-
alization and subsequent image-guided biopsies are therefore
imperative.
Recent advances in MRI techniques for detecting and
localizing prostate cancer have improved the aforementioned
scenario. Many studies reported that MRI-guided targeted
biopsies in patients with elevated PSA levels and negative
systematic TRUS-guided biopsy detected cancer in 21% to
52% of patients, although the MRI protocol and guided-biopsy
methods varied.4,10e13,15 In this study, we prospectively per-
formed MRI scans and subsequently targeted TRUS-guided
biopsy with cognitive registration. The MRI scans showed
positive results in 35.4% patients, and the overall cancer-yield
rate was 21%. This result substantiates the benefits of MRI-
guided targeted prostate biopsy for patients with contra-
dicting results of negative biopsies and persistently elevated
PSA levels. Among the eight cancer patients in our study who
underwent surgery, five had T3-stage disease and only three
had T2 disease, indicating that the diagnosis solely through
systematic TRUS-guided biopsy could have resulted in over-
looking severe lesions and delaying treatment. Furthermore,
the results of our study were consistent with previous studies
reporting that systematic TRUS-guided biopsy usually misses
detection of tumors located at the apex, transition zone, and
anterior horns of the peripheral zone of the prostate
gland.19e22
There remains a concern that significant cancers may be
missed if a standard systematic biopsy is omitted. Sonn et al15
studied 105 patients with elevated PSA levels and negative
biopsies, and systematic biopsies were performed regardless of
MRI scans, with target biopsy performed for those patients
with positive MRI results. Targeted biopsy detected a higher
percentage of significant cancer as compared with systematic
biopsy; however, ~10% of the patients diagnosed with sig-
nificant cancer showed no suspicious lesions on MR images.
Siddiqui et al23 studied 1003 patients and found that 3%
yielded intermediate or high-risk disease via systematic bi-
opsy, with no lesion detected according to mpMRI. Therefore,
although mpMRI results that are negative for prostate cancer
are reported to show >95% negative-predictive value for
clinically significant cancer,24,25 there is still controversyregarding whether a targeted biopsy can completely replace
systematic biopsy. However, concurrent standard 12-core
systematic biopsy and target biopsy indicates that taking >16
biopsy cores and >20 cores in cases with more than two target
lesions raises the concern of increasing complications. In our
study, the option of systematic biopsy was informed and dis-
cussed with the patients, with most opting for targeted biopsy
only. The strategy of targeted biopsies for high-risk lesions has
the advantage of obtaining fewer biopsy cores and causing
fewer complications, and, therefore, has been adopted in our
clinical practice. By active surveillance and further follow-ups
of the noncancer-yield patients, treatment of potentially un-
detected cancer would not be delayed.
Degree of suspicion based on MRI scans was the most
powerful predictor of significant cancer according to multi-
variate analysis,15 and a higher MRI-suspicion score was
associated with a higher detection rate of significant prostate
cancer.26,27 Previously, few studies on MRI-guided targeted
prostate biopsy designed their own risk stratification of the
lesions detected by MRI.15,23,27 In 2013, the ESUR published
a unified scoring system called PI-RADS to establish technical
and reporting standards for consistent interpretation and
communication of prostate mpMRI results.16 In 2015, a
refined version of PI-RADS (v2) was developed in conjunction
with the American College of Radiology, which used a five-
point scale to indicate the likelihood of significant prostate
cancer based on mpMR findings.17 So far, limited studies have
incorporated the PI-RADS (v2) scoring system for targeted
biopsy.28 In our study, we applied the PI-RADS (v2) assess-
ment to the imaging analysis and found that the cancer-yield
rate for score-4 lesions was much lower than that for the
score-5 lesions, which agrees with results from previous re-
ports. However, only three biopsy scores were obtained from
all targeted lesions, and there may remain an increased chance
of mis-targeting for smaller lesions. The existing evidence is
insufficient to determine whether the lower cancer-yield rate
associated with lower-risk lesions are due to mis-targeting and
whether increasing the number of biopsies is necessary to
yield the most significant cancer results for lesions of a lower-
risk category.29 Active surveillance and further follow-ups for
the noncancer-yield patients are required to provide answers to
these questions.
An MRI procedure can be very expensive, and routine
prebiopsy MRI may be a large financial burden on the
healthcare system. To avoid unnecessary biopsy and exces-
sive use of MRI facilities, defining more strict clinical criteria
for prebiopsy MRI is essential. In this study, we found that
PSATZ was the most significantly different PSA-related data
between the cancer-yield and noncancer-yield groups. Our
results were consistent with those of Margel et al,22 sug-
gesting that PSA density increased in patients with lesion size
>1 cm as detected through MRI scans and compared with
those exhibiting normal MRI results (0.15 vs. 0.07 ng/mL/
cm3; p¼ 0.018). One of the major sources of serum PSA is
leakage from the transition zone; therefore, the volume
detected in the transition zone is strongly associated with
serum PSA level.30 Dividing the serum PSA level by the
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influence of BPH, thus enhancing the probability of prostate
cancer existence. In this study, the cut-off value of 0.45 ng/
mL/cm3 resulted in a high sensitivity of 90% for highly
suspicious lesions found through MRI scans. Therefore, we
recommend the measurement of transitional zone volume as a
standard part of TRUS, because this may constitute a useful
criterion for selecting patients for prebiopsy MRI and sub-
sequently avoid excessive MRI use.
Different techniques associated with MRI-guided targeted
biopsy are used in different institutions and dependent upon
available technical and manpower resources. Direct MRI-
guided targeted biopsy has been adapted for guiding biopsy
procedures31; however, MRI is time intensive and expensive. A
combination of MRI for cognitive registration and TRUS-
guided biopsy is clinically practical and requires no expen-
sive or complex techniques. Image registration between the
mpMRI and ultrasound images is achieved either by fusion
software or cognitive fusion. Although a study using a vali-
dated TRUS prostate-biopsy simulator reported that MRI-
targeted TRUS-guided prostate biopsy using cognitive regis-
tration was inferior to software fusion,32 it was reported that
software fusion and cognitive fusion do not differ signifi-
cantly.33,34 In our experience, all lesions with PI-RADS scores
of 4 or 5 could be identified through TRUS images with known
MRI results. Additional verification is necessary to determine
whether software fusion is helpful to yield small-lesion deter-
mination. Transperineal template prostate-mapping biopsy is
another popular method for guided biopsy,26,35 whereas general
anesthesia is required for this method; however, no compara-
tive data are available for the aforementioned methods.
Several limitations existed for this study, with the first and
major one being the small sample size. Second, only highly
suspicious lesions detected through MRI received MRI-guided
targeted biopsy, and systematic biopsies were not performed
for all patients. Some significant cancers can potentially be
missed. Last and most importantly, long-term follow-up re-
sults were not available, and the false-negative rate associated
with this approach is, therefore, not available.
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